Enhanced Group（K7J）株式概要Enhanced Group Inc.は、臨床監督のもとでパフォーマンス強化の使用を許可する一連のエリートスポーツ大会、Enhanced Gamesを企画・運営している。 詳細K7J ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より82.7%で取引されている 収益は年間86.1%増加すると予測されています リスク分析株式の流動性は非常に低い マイナスの株主資本 収益が 100 万ドル未満 ( $3K )すべてのリスクチェックを見るK7J Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,274 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG487,274 investors already sharing narrativesYour Fair Value€Current Price€2.504.2m% 割高 内在価値ディスカウントEst. Revenue$PastFuture-103m61k2016201920222025202620282031Revenue US$61.5kEarnings US$2.7kAdvancedSet Fair ValueView all narrativesEnhanced Group Inc. 競合他社Borussia Dortmund GmbH Kommanditgesellschaft auf AktienSymbol: XTRA:BVBMarket cap: €335.0mEdel SE KGaASymbol: XTRA:EDLMarket cap: €107.4mHighlight CommunicationsSymbol: XTRA:HLGMarket cap: €36.9mSCP Standard Capital PartnersSymbol: XTRA:CAPMarket cap: €32.8m価格と性能株価の高値、安値、推移の概要Enhanced Group過去の株価現在の株価US$2.5052週高値US$4.9252週安値US$2.42ベータ01ヶ月の変化-0.80%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-30.80%最新ニュースお知らせ • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.お知らせ • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.お知らせ • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元K7JDE Specialty RetailDE 市場7D0%0.1%-0.5%1Yn/a-13.3%-2.1%株主還元を見る業界別リターン: K7JがGerman Specialty Retail業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: K7J German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is K7J's price volatile compared to industry and market?K7J volatilityK7J Average Weekly Movementn/aSpecialty Retail Industry Average Movement5.0%Market Average Movement5.5%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.8%安定した株価: K7Jの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のK7Jのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a22Max Martinwww.enhanced.comエンハンスド・グループ・インクは、臨床監督のもとでパフォーマンス強化の使用を許可する一連のエリート・スポーツ大会であるエンハンスド・ゲームズを企画・運営している。同社は、参加アスリートに医学的監督とサポートを提供し、スポーツ科学に関連する科学的研究の設計と実施をサポートしています。また、研究結果を科学界や一般に発信し、エリート競技における透明性を提唱し、アスリートの健康評価の基準を設定することを目指している。アスリートがその功績を認められ、報酬を受け取るためのプラットフォームを提供している。同社は、科学的なスポーツ研究や競技に携わるアスリートや団体など、エリートスポーツ分野の顧客にサービスを提供している。本社はニューヨーク州ニューヨーク。もっと見るEnhanced Group Inc. 基礎のまとめEnhanced Group の収益と売上を時価総額と比較するとどうか。K7J 基礎統計学時価総額€281.41m収益（TTM）-€34.83m売上高(TTM)€2.41kOver9,999xP/Sレシオ-8.1xPER（株価収益率K7J は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計K7J 損益計算書（TTM）収益US$2.76k売上原価US$0売上総利益US$2.76kその他の費用US$39.79m収益-US$39.78m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.33グロス・マージン100.00%純利益率-1,444,024.97%有利子負債／自己資本比率0%K7J の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/09 01:49終値2026/07/01 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enhanced Group Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Matthew AbrahamBerenbergSusan AndersonCanaccord GenuityAlex FuhrmanLucid Capital Markets
お知らせ • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.
Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.
お知らせ • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.
Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.
Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.
お知らせ • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.
Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
